Paradigm Capital Management Inc. NY Has $43.40 Million Holdings in Orthofix Medical Inc. (NASDAQ:OFIX)

Paradigm Capital Management Inc. NY decreased its holdings in Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 2.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,485,900 shares of the medical device company's stock after selling 70,600 shares during the period. Orthofix Medical comprises 2.0% of Paradigm Capital Management Inc. NY's portfolio, making the stock its 15th largest holding. Paradigm Capital Management Inc. NY owned about 6.51% of Orthofix Medical worth $43,404,000 as of its most recent SEC filing.

A number of other hedge funds have also made changes to their positions in the stock. Lazard Asset Management LLC acquired a new position in Orthofix Medical in the 4th quarter valued at approximately $45,000. R Squared Ltd purchased a new position in shares of Orthofix Medical during the 4th quarter valued at $50,000. KLP Kapitalforvaltning AS purchased a new position in shares of Orthofix Medical during the 4th quarter valued at $112,000. Tower Research Capital LLC TRC increased its stake in shares of Orthofix Medical by 120.8% in the fourth quarter. Tower Research Capital LLC TRC now owns 8,458 shares of the medical device company's stock worth $148,000 after acquiring an additional 4,627 shares during the last quarter. Finally, State of Wyoming raised its holdings in shares of Orthofix Medical by 206.8% during the fourth quarter. State of Wyoming now owns 9,432 shares of the medical device company's stock worth $165,000 after acquiring an additional 6,358 shares in the last quarter. 89.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have commented on OFIX. StockNews.com downgraded Orthofix Medical from a "buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Canaccord Genuity Group reiterated a "buy" rating and set a $24.00 price target on shares of Orthofix Medical in a report on Wednesday, February 26th. Finally, Roth Mkm restated a "buy" rating and issued a $22.00 price objective on shares of Orthofix Medical in a report on Wednesday, February 26th.

Insider Buying and Selling at Orthofix Medical

In other news, CEO Massimo Calafiore bought 10,000 shares of the stock in a transaction that occurred on Friday, May 9th. The shares were acquired at an average cost of $12.54 per share, for a total transaction of $125,400.00. Following the purchase, the chief executive officer now owns 234,603 shares of the company's stock, valued at $2,941,921.62. This represents a 4.45% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Lucas Vitale sold 4,287 shares of the business's stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $16.60, for a total transaction of $71,164.20. Following the transaction, the insider now directly owns 135,317 shares of the company's stock, valued at approximately $2,246,262.20. This represents a 3.07% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 8,475 shares of company stock worth $128,065 over the last three months. Corporate insiders own 1.30% of the company's stock.

Orthofix Medical Stock Down 0.7%

OFIX stock opened at $12.06 on Tuesday. The firm has a market cap of $470.61 million, a PE ratio of -3.85 and a beta of 0.87. Orthofix Medical Inc. has a 1 year low of $10.50 and a 1 year high of $20.73. The company has a fifty day simple moving average of $14.29 and a 200 day simple moving average of $16.75. The company has a current ratio of 2.39, a quick ratio of 1.11 and a debt-to-equity ratio of 0.25.

About Orthofix Medical

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.

Want to see what other hedge funds are holding OFIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Orthofix Medical Inc. (NASDAQ:OFIX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.